Ibrutinib Above 79 Years Old for Chronic Lymphocytic Leukemia: Important Toxicities

Abstract

12 patients receiving rivaroxaban 20 mg once a day (n = 6), dabigatran 150 mg twice a day (n = 2), apixaban 5 mg twice a day (n = 4) for periods ranging from 9 to 25 months with Ib therapy no hemorrhagic manifestations have been observed. Conclusions: Hemorrhagic manifestations occurring in CLL patientsreceiving NOAC and Ib treatment were not life-threatening, in most cases did not require the abolition of NOAC and a dose reduction of Ib. The development of thrombocytopenia was the main reason for the abolition of NOAC in patients with CLL.